2024
Acute Promyelocytic Leukemia in the Real World: Understanding Outcome Differences and How We Can Improve Them
Bidikian A, Bewersdorf J, Kewan T, Stahl M, Zeidan A. Acute Promyelocytic Leukemia in the Real World: Understanding Outcome Differences and How We Can Improve Them. Cancers 2024, 16: 4092. PMID: 39682277, PMCID: PMC11640703, DOI: 10.3390/cancers16234092.Peer-Reviewed Original ResearchAcute promyelocytic leukemiaAdvent of all-trans retinoic acidEarly mortalityLong-term treatment toxicitiesArsenic trioxidePromyelocytic leukemiaClinical practiceIncidence of acute promyelocytic leukemiaRates of remissionLong-term outcomesTreatment of acute promyelocytic leukemiaLong-term survivalComprehensive patient evaluationResource-limited settingsTreatment toxicityAll-trans retinoic acidDelayed diagnosisPatient demographicsSignificant comorbiditiesTreatment initiationOlder patientsExpert centersClinical trialsTreatment outcomesReal-world settings
2011
Impact of a Venous Thromboembolism Prophylaxis “Smart Orderset”: Improved Compliance, Fewer Events
Zeidan A, Streiff M, Ahmed S, Kraus P, Hobson D, Horn P, Shermock K, Tinoco G, Haut E. Impact of a Venous Thromboembolism Prophylaxis “Smart Orderset”: Improved Compliance, Fewer Events. Blood 2011, 118: 172. DOI: 10.1182/blood.v118.21.172.172.Peer-Reviewed Original ResearchVTE risk factorsVTE prophylaxisRisk factorsSymptomatic VTEMajor bleedingPharmacologic prophylaxisPatient demographicsExact testRetrospective cohort chart reviewRisk-appropriate VTE prophylaxisCohort chart reviewOutcome adjudication committeeRisk of VTEVTE prophylaxis guidelinesVTE prophylaxis recommendationsPost-hospital dischargeVenous thromboembolism prophylaxisSanofi-AventisPrimary outcome measureFisher's exact testT-testStudent's t-testDaily heparinHospital VTEProphylaxis guidelines